On June 25, 2024, eFFECTOR Therapeutics, Inc. (the "Company") received written notice from Oxford Finance LLC ("Oxford") that events of default have occurred with respect to that certain Loan and Security Agreement dated as of March 19, 2021, as amended (the "Loan and Security Agreement"), by and between Oxford, as collateral agent, the parties who are lenders thereunder, the Company and eFFECTOR Therapeutics Operations, Inc., the Company's wholly owned subsidiary (the "Oxford Notice").

The Oxford Notice indicates that events of default have occurred under the Loan and Security Agreement's Section 8.3 (Material Adverse Change) and Section 8.5 (Insolvency). The Oxford Notice indicates that all obligations are now immediately due and payable, the obligations under the Loan and Security Agreement shall accrue interest at the default rate, and lender and agent reserve all rights, powers, privileges and remedies provided under the Loan and Security Agreement.